Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology Pub Date : 2025-04-14 DOI:10.1016/j.oraloncology.2025.107246

Anouk V.M. Burger , Melissa A. Koot , Dorieke E.M. van Balen , Anouk W.M.A. Schaeffers , Charlotte L. Zuur , Lot A. Devriese , Micha de Ridder , Alex E. Hoetink , Tim Schutte , Mirjam Crul

{"title":"Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation","authors":"Anouk V.M. Burger , Melissa A. Koot , Dorieke E.M. van Balen , Anouk W.M.A. Schaeffers , Charlotte L. Zuur , Lot A. Devriese , Micha de Ridder , Alex E. Hoetink , Tim Schutte , Mirjam Crul","doi":"10.1016/j.oraloncology.2025.107246","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin-based chemoradiation often suffer from cisplatin-induced hearing loss (CIHL). To prevent toxicities, patients receive hydration before and after cisplatin infusions. This study evaluated cisplatin-induced hearing loss between a long and short duration of infusion and volume of hydration schedule (DIVHS).</div></div><div><h3>Methods</h3><div>Between 2019 and 2023, 161 patients were included in two Dutch hospitals. Patients received either weekly cisplatin (Cis40qw, n = 77) or triweekly cisplatin (Cis1003q3w, n = 88). Two different short and long DIVHS were used in each cisplatin regimen. Pure tone audiometry was performed at baseline and three months after chemoradiation. Pure tone averages (PTA) were calculated for PTA 1–2–4 kHz and PTA 8–10–12.5 kHz. CIHL was assessed using mean threshold shift.</div></div><div><h3>Results</h3><div>In the Cis40qw group, the mean threshold shift at PTA 1–2–4 kHz was 3.1 dB in the short and 4.7 dB in the long DIVHS (<em>p</em> = 0.37). In the Cis100q3w cohort, the mean threshold shift was 5.3 dB in the short and 7.1 dB in the long DIVHS (<em>p</em> = 0.36). At PTA 8–10–12.5 kHz, the mean threshold shifts of the Cis40qw groups were 11.8 dB in the short versus 15.4 dB in the long DIVHS (<em>p</em> = 0.30). In the Cis100q3w cohort, the mean threshold shift was 19.9 dB in the short compared to 19.4 dB in the long DIVHS (<em>p</em> = 0.85).</div></div><div><h3>Conclusion</h3><div>This study found no significant difference in CIHL between different DIVHS during cisplatin-based chemoradiation in HNSCC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107246"},"PeriodicalIF":4.0000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368837525000752","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin-based chemoradiation often suffer from cisplatin-induced hearing loss (CIHL). To prevent toxicities, patients receive hydration before and after cisplatin infusions. This study evaluated cisplatin-induced hearing loss between a long and short duration of infusion and volume of hydration schedule (DIVHS).

Methods

Between 2019 and 2023, 161 patients were included in two Dutch hospitals. Patients received either weekly cisplatin (Cis40qw, n = 77) or triweekly cisplatin (Cis1003q3w, n = 88). Two different short and long DIVHS were used in each cisplatin regimen. Pure tone audiometry was performed at baseline and three months after chemoradiation. Pure tone averages (PTA) were calculated for PTA 1–2–4 kHz and PTA 8–10–12.5 kHz. CIHL was assessed using mean threshold shift.

Results

In the Cis40qw group, the mean threshold shift at PTA 1–2–4 kHz was 3.1 dB in the short and 4.7 dB in the long DIVHS (p = 0.37). In the Cis100q3w cohort, the mean threshold shift was 5.3 dB in the short and 7.1 dB in the long DIVHS (p = 0.36). At PTA 8–10–12.5 kHz, the mean threshold shifts of the Cis40qw groups were 11.8 dB in the short versus 15.4 dB in the long DIVHS (p = 0.30). In the Cis100q3w cohort, the mean threshold shift was 19.9 dB in the short compared to 19.4 dB in the long DIVHS (p = 0.85).

Conclusion

This study found no significant difference in CIHL between different DIVHS during cisplatin-based chemoradiation in HNSCC patients.

查看原文本刊更多论文

顺铂类放化疗对头颈部鳞状细胞癌患者不同输注时间和水化量所致听力损失的影响

头颈部鳞状细胞癌（HNSCC）患者接受以顺铂为基础的放化疗后，常出现顺铂性听力损失（CIHL）。为防止毒性反应，患者在顺铂输注前后均接受水化治疗。本研究评估了顺铂引起的听力损失在输注时间长短和水化量计划（DIVHS）之间的差异。方法2019年至2023年，在荷兰两家医院纳入161例患者。患者接受每周一次的顺铂治疗（Cis40qw, n = 77）或三周的顺铂治疗（Cis1003q3w, n = 88）。在每个顺铂方案中使用两种不同的短、长DIVHS。在基线和放化疗后3个月进行纯音听力测定。计算了PTA 1-2-4 kHz和PTA 8-10-12.5 kHz的纯音平均值（PTA）。CIHL采用平均阈值移位评估。结果Cis40qw组在PTA 1-2-4 kHz处的平均阈值移位短为3.1 dB，长为4.7 dB （p = 0.37）。在Cis100q3w队列中，短时间的平均阈值移位为5.3 dB，长时间的平均阈值移位为7.1 dB （p = 0.36）。在PTA 8-10-12.5 kHz时，Cis40qw组的平均阈值漂移在短时间内为11.8 dB，而在长时间内为15.4 dB （p = 0.30）。在Cis100q3w队列中，短时间的平均阈值移位为19.9 dB，而长时间的平均阈值移位为19.4 dB （p = 0.85）。结论本研究发现不同DIVHS在HNSCC患者顺铂化放化疗期间CIHL无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral oncology 医学-牙科与口腔外科

CiteScore

8.70

自引率

10.40%

发文量

505

审稿时长

20 days

期刊介绍： Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck. Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.